Mogelijk gemaakt door 
Translate
Translate
26 March 2026
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Investor Presentation
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc. and the name change to Coiled Therapeutics plc, effective 27 March 2026, the leadership team will host a live interactive presentation on the Engage Investor platform, on Monday 30 March 2026, at 2:00pm BST.
Dr Sotirios Stergiopoulos, Chairman Coiled Therapeutics and Sridhar Vempati, CEO Coiled Therapeutics (together with Stephen West, current Chairman of Roquefort Therapeutics) will present.
The Company welcomes all current shareholders and interested investors to join, and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.
Investors can sign up to Engage Investor at no cost and follow the Company from their personalised investor hub, and can register interest in this event here:
https://engageinvestor.news/ROQ_IP_0326
-ENDS-
|
Roquefort Therapeutics plc Stephen West (Chairman)
|
+44 (0)20 3918 8633 |
|
SP Angel Corporate Finance LLP (Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino
|
+44 (0)20 4530 6926
+61 (0)8 9223 2222 |
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
